🏆🎗️𝐓𝐡𝐞 𝐘𝐯𝐨𝐧𝐧𝐞 𝐀𝐰𝐚𝐫𝐝𝐬 𝟐𝟎𝟐𝟔 𝐁𝐫𝐨𝐮𝐠𝐡𝐭 𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐲’𝐬 𝐂𝐡𝐚𝐧𝐠𝐞𝐦𝐚𝐤𝐞𝐫𝐬 𝐭𝐨 𝐂𝐡𝐢𝐜𝐚𝐠𝐨

A Wonderful President Dinner at #EHA2026 - @jjkiladjian oncodaily.com/voices/jean-ja…

Honored to Be Featured in @CancerWorldmag Magazine - Mohamed Emam Sobeih oncodaily.com/voices/mohamed…

A Shift Beyond Plasma Cell–Directed Therapy Alone in AL Amyloidosis at #EHA26 - @SergeyBadalyan1 oncodaily.com/voices/sergey-…

Thrilled to Have Received the EHA 2026 Education and Mentoring Award - @DrRaulCordoba @sehh_es oncodaily.com/voices/raul-co…

New EPCORE DLBCL-3 Data on Epcoritamab in First-Line DLBCL - @DrRaulCordoba oncodaily.com/voices/raul-co…

🎀 The INAVO120 safety analysis brings an important practical message: efficacy matters, but manageability determines real-world use. Published in ESMO Open, this analysis evaluated the safety profile of inavolisib plus palbociclib–fulvestrant in patients with PIK3CA-mutated, HR-positive, HER2-negative, endocrine-resistant advanced breast cancer. The INAVO120 regimen had already shown improved PFS and OS. This analysis focused on how clinicians can manage key selected adverse events: 📌 Hyperglycaemia 📌 Stomatitis/mucosal inflammation 📌 Rash 📌 Diarrhoea Most of these events occurred early, especially during the first treatment cycles, and were generally manageable with supportive medications and dose modifications. Key safety points: ➡️ Hyperglycaemia was mostly grade 1–2 and commonly managed with metformin ➡️ Stomatitis/mucosal inflammation was often managed with dexamethasone mouthwash ➡️ Rash was mostly low grade, with no grade 3–5 events reported ➡️ Diarrhoea was usually short-lived and commonly managed with loperamide ➡️ No new or unexpected safety signals were observed The takeaway: INAVO120 supports the use of inavolisib plus palbociclib–fulvestrant as an effective regimen with a safety profile that can be managed through early monitoring, patient education, supportive care, and dose modification. Reference: Im et al., ESMO Open, 2026. @jhaveri_komal @LoiSher @ErikaHamilton9 @evaciruelos oncodaily.com/oncolibrary/br…

🎀 A HER2 bispecific antibody has now challenged the global first-line standard in HER2-positive advanced breast cancer. Alphamab Oncology announced that the phase III KN026-003 trial met its primary endpoint. The study evaluated anbenitamab (KN026) plus HB1801, an albumin-bound docetaxel, as first-line treatment for HER2-positive advanced breast cancer. The comparator was the current standard first-line regimen: ➡️ trastuzumab ➡️ pertuzumab ➡️ docetaxel also known as THP According to the company, KN026 plus HB1801 significantly prolonged progression-free survival versus THP, with a statistically significant and clinically meaningful benefit. The study also showed a trend toward overall survival benefit and a favorable safety profile. Why this matters: KN026 is designed to bind two non-overlapping HER2 epitopes, domain IV and domain II, aiming to block HER2 signaling more comprehensively than conventional single-target antibody approaches. This is a major topline signal for HER2 bispecific antibody-based therapy in breast cancer. The full dataset is still needed. Key questions remain: 📌 What was the median PFS? 📌 What was the hazard ratio? 📌 How strong was the OS trend? 📌 Which subgroups benefited most? 📌 How did safety compare with THP? 📌 Could this support a “first-line bispecific, second-line ADC” sequencing strategy? For now, KN026-003 positions anbenitamab plus HB1801 as one of the most closely watched HER2-positive breast cancer datasets ahead of its full presentation. oncodaily.com/oncolibrary/br… #OncoDailyBreast #AlphamabOncology

Giannis Mountzios Discusses Tarlatamab’s Intracranial Efficacy in SCLC with The ASCO Post @g_mountzios @ASCO

🫁 In PD-L1-negative advanced NSCLC, the choice of first-line immunotherapy combination may matter. A multicenter retrospective cohort study published in Lung Cancer compared two widely used first-line regimens in advanced NSCLC without actionable driver mutations: ➡️ Nivolumab ipilimumab chemotherapy ➡️ Pembrolizumab chemotherapy The analysis included 457 patients treated across 13 institutions in Japan. Patients were stratified by PD-L1 tumor proportion score: 📌 PD-L1 TPS <1% 📌 PD-L1 TPS ≥1% The strongest signal came from the PD-L1-Negative Advanced NSCLC cohort. With follow-up exceeding 40 months, nivolumab plus ipilimumab with chemotherapy showed longer overall survival than pembrolizumab with chemotherapy: 📌 Median OS: 47.4 vs 16.6 months 📌 Adjusted HR: 0.50 📌 36-month OS rate: 51.5% vs 28.2% In patients with PD-L1 TPS ≥1%, survival outcomes were similar between the two regimens. Safety was broadly comparable, although severe skin toxicity and adrenal-pituitary disorders were more frequent with nivolumab plus ipilimumab. The takeaway: For PD-L1-Negative Advanced NSCLC, dual checkpoint blockade plus chemotherapy may provide a sustained long-term survival advantage — but prospective validation is still needed. Reference: Kinehara et al., Lung Cancer, 2026. #OncoDailyLung #NSCLC

IASLC Update on Pulmonary NENs Classification - Nieves Martínez Lago @DraMartinezLago

Nivolumab–Ipilimumab Plus Chemotherapy Shows Longer OS in PD-L1-Negative NSCLC - Diego A. Díaz García @diegoadiazg

The 2026 AACR Cancer Disparities Progress Report Highlights Successes, Gaps, and a Call to Action - @MarianaStern @AACR oncodaily.com/voices/mariana…

Youth Cancer Europe - Strengthening Representation and Representativeness in Clinical Studies @CancerEurope oncodaily.com/voices/youth-c…

The Yvonne Awards 2026 | May 29, Chicago The Yvonne Awards 2026 Ceremony brought together some of the most influential voices in global oncology during the @ASCO 2026 Annual Meeting in Chicago to celebrate excellence, innovation, leadership, mentorship, advocacy, and humanitarian service in cancer care. Hosted by OncoDaily, and with @NateraGenetics the exclusive partner of Yvonne Awards Ceremony and OncoDaily Reception, the ceremony honored outstanding clinicians, researchers, educators, patient advocates, and healthcare leaders whose work is transforming oncology across the world. From groundbreaking research and AI-driven innovations to community oncology, global health initiatives, pediatric cancer care, mentorship, humanitarian efforts, and lifetime achievements, the evening highlighted the individuals shaping the future of cancer care and improving the lives of patients everywhere. The Yvonne Awards 2026 winners are: Breakthrough Research - Hasmukh Jain Challenging the Status Quo - @AnaVManana Challenging the Status Quo Nickhill Bhakta AI in Oncology by @ZSAssociates - @ca_chung AI in Oncology by @ZSAssociates - @AbhishekDGarg Community Oncology - Joanna Metzner-Sadurski Community Oncology - Hannatu Ayuba Usman Global Oncology - @NabeelZafarMD Leadership - @herbloong Mentorship - Samvel Bardakhchyan Mentorship -@adawaksmd Pediatric Oncology - @Drellaamoako Humanitarian Award - Mohammad I. M. Hojouj Lifetime achievement award - @charlesbalchmd Lifetime achievement award - Eduardo Cazap Voice of Oncology - @SuyogCancer The ceremony featured inspiring acceptance speeches, personal reflections, and powerful stories from award recipients representing diverse regions and disciplines. Honorees shared their experiences advancing equitable cancer care, pioneering novel therapies, strengthening healthcare systems, mentoring the next generation of oncologists, and delivering hope to patients under the most challenging circumstances. youtu.be/Ri3hpiTXGQE #YvonneAwards2026